These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22321702)

  • 1. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan.
    Hirata Y; Ohmae T; Yanai A; Sakitani K; Hayakawa Y; Yoshida S; Sugimoto T; Mitsuno Y; Akanuma M; Yamaji Y; Ogura K; Maeda S; Koike K
    Int J Antimicrob Agents; 2012 Apr; 39(4):352-5. PubMed ID: 22321702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.
    Mori H; Suzuki H; Matsuzaki J; Tsugawa H; Fukuhara S; Miyoshi S; Hirata K; Seino T; Matsushita M; Masaoka T; Kanai T
    Helicobacter; 2016 Aug; 21(4):286-94. PubMed ID: 26612407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.
    Nishizawa T; Suzuki H; Nakagawa I; Iwasaki E; Masaoka T; Hibi T
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S167-70. PubMed ID: 19120892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea.
    Lee JW; Kim N; Nam RH; Park JH; Kim JM; Jung HC; Song IS
    Helicobacter; 2011 Aug; 16(4):301-10. PubMed ID: 21762270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.
    Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
    Digestion; 2020; 101(5):644-650. PubMed ID: 31387107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.
    Hirata Y; Serizawa T; Shichijo S; Suzuki N; Sakitani K; Hayakawa Y; Yamada A; Koike K
    Int J Infect Dis; 2016 Oct; 51():66-69. PubMed ID: 27590563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan.
    Hung KH; Sheu BS; Chang WL; Wu HM; Liu CC; Wu JJ
    Helicobacter; 2009 Feb; 14(1):61-5. PubMed ID: 19191898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.
    Sugimoto M; Sahara S; Ichikawa H; Kagami T; Ban H; Otsuka T; Andoh A; Furuta T
    Helicobacter; 2017 Feb; 22(1):. PubMed ID: 27213463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility.
    Cattoir V; Nectoux J; Lascols C; Deforges L; Delchier JC; Megraud F; Soussy CJ; Cambau E
    Int J Antimicrob Agents; 2007 Apr; 29(4):389-96. PubMed ID: 17303392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan.
    Chang WL; Kao CY; Wu CT; Huang AH; Wu JJ; Yang HB; Cheng HC; Sheu BS
    Helicobacter; 2012 Jun; 17(3):210-5. PubMed ID: 22515359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium.
    Bogaerts P; Berhin C; Nizet H; Glupczynski Y
    Helicobacter; 2006 Oct; 11(5):441-5. PubMed ID: 16961806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan.
    Miyachi H; Miki I; Aoyama N; Shirasaka D; Matsumoto Y; Toyoda M; Mitani T; Morita Y; Tamura T; Kinoshita S; Okano Y; Kumagai S; Kasuga M
    Helicobacter; 2006 Aug; 11(4):243-9. PubMed ID: 16882327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance.
    Chung JW; Lee GH; Jeong JY; Lee SM; Jung JH; Choi KD; Song HJ; Jung HY; Kim JH
    J Gastroenterol Hepatol; 2012 Mar; 27(3):493-7. PubMed ID: 21793912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection.
    Cammarota G; Martino A; Pirozzi G; Cianci R; Branca G; Nista EC; Cazzato A; Cannizzaro O; Miele L; Grieco A; Gasbarrini A; Gasbarrini G
    Aliment Pharmacol Ther; 2004 Apr; 19(7):789-95. PubMed ID: 15043520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure.
    Ueki N; Miyake K; Kusunoki M; Shindo T; Kawagoe T; Futagami S; Tsukui T; Inagaki H; Sakamoto C
    Helicobacter; 2009 Apr; 14(2):91-9. PubMed ID: 19298336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study.
    Assem M; El Azab G; Rasheed MA; Abdelfatah M; Shastery M
    Eur J Intern Med; 2010 Aug; 21(4):310-4. PubMed ID: 20603042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal.
    Miftahussurur M; Shrestha PK; Subsomwong P; Sharma RP; Yamaoka Y
    BMC Microbiol; 2016 Nov; 16(1):256. PubMed ID: 27809767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB.
    Rimbara E; Noguchi N; Kawai T; Sasatsu M
    Helicobacter; 2012 Feb; 17(1):36-42. PubMed ID: 22221614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
    Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Yamada T; Osawa S; Sugimoto K; Watanabe H; Umemura K
    J Gastroenterol Hepatol; 2014 Mar; 29(3):487-93. PubMed ID: 24224808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.